Study to Evaluate the Efficacy and Safety of RZ402 in Diabetic Macular Edema (DME)

NCT05712720 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

94

Enrollment

OTHER

Sponsor class

Conditions

Diabetic Macular Edema

Interventions

DRUG: Experimental: Group 1 - 50mg RZ402
DRUG: Experimental: Group 2 - 200mg RZ402
DRUG: Experimental: Group 3 - 400mg RZ402
OTHER: Placebo: Group 4 - Placebo

Sponsor

Rezolute